Latest Content

Updated guidelines set lower systolic blood pressure goals, expanded risk-based treatment, and call for stronger implementation to close care gaps.

AI and digital tools are reshaping breast cancer care—from screening and trials to remote monitoring and lifestyle support.

One in 5 of the highest-revenue drugs of 2022 was exclusively approved for rare conditions, accounting for more than 7% of US pharmaceutical spending.

To ease decision making for busy oncologists, Natera integrates molecular testing into Flatiron Health's OncoEMR, streamlining workflows with the goal of improving patient outcomes.

Papillary muscle scarring has a substantial association with both cardiovascular mortality and arrhythmia.

Early measles vaccination among Texas infants surged in early 2025, likely helping reduce their risk amid the nation's largest outbreak since 2000.

This study examines the clinical settings of first-time psychotic spectrum disorder diagnoses in an integrated health system.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Experts say proposed pharmaceutical tariffs could raise drug prices, impacting patient access and health care budgets.